immunoglobulin A nephropathy

Filspari fails to confirm kidney benefit in IgAN, but Travere hopes to keep FDA approval

Half a year after securing accelerated approval for the treatment of a rare kidney ailment, Travere Therapeutics’ groundbreaking drug, Filspari, ...